Impact of China on the Pharmaceutical Industry - Thematic Research

2021-06-30
Price :
Published : Jun-2021
No. of Pages : 117
Table of Contents
Abbreviations
Related Reports
Executive Summary
Key Findings
Introduction
National Strategic Plans and Regulatory Reforms Are Driving Growth and Transformation of the Chinese Pharma Market
Big Pharma Is Investing in China with Deals and Investment in R&D Centers
Overview of Disease Prevalence in China
Forecast Diagnosed Prevalence of Top Indications in China
Key Influencer Twitter Chat Related to China
Trends
The China Pharma Market Is Dominated By Generics
The Biosimilars Market Is Set to Expand
China Is Striving to Build Its Regenerative Medicine Sector
China Is Also Building Its Immuno-Oncology Footprint
China Has Strong Manufacturing and Outsourcing Capabilities
Plans to Boost Manufacturing in West China
Made in China 2025 Aims to Drive Further Manufacturing in China
Drug Pricing Reforms to Increase Access to Innovative Drugs
Medical Tourism Is Developing in China
US-China Relations
Shedding the Pharma Industry's Poor Reputation in China
Healthy China 2030 Aims to Improve the Overall Health of the Chinese Population
Regulatory Reforms to Attract Overseas Companies
China Is a Global Leader in 5G
China's Emerging 3D Printing Industry
Value Chain
Market Analysis
China Pharma Market Expected to See Major Growth by 2029
The Number of Pharma Deals in China Has Increased Since 2017
Funding and Strategic Alliances Are Leading Deal Types in China
Acquisitions Lead M&A Activity in China
Top 10 M&A Deals 2018-2021: Chinese Companies
Top 10 M&A Deals 2018-2021: International Companies
Licensing Agreements and Oncology Dominate Strategic Partnerships
Examples of Strategic Partnerships 2018-2021: Chinese Companies
Examples of Strategic Partnerships 2018-2021: International Companies
Financing Focuses on Biologics in Oncology across China
Top Funding Deals 2018-2021: Chinese Entities
Examples of Emerging Technology Deals 2018-2021
China Pharma Market Jobs Analysis
Clinical Trials
The Number of Clinical Trials in China Has Risen Over the Past Decade
The Majority of Trials in China Are Early Phase
Oncology Indications Dominate Clinical Trials in China
The Majority of Clinical Trials in China Are Run by Chinese Entities
Top 10 Clinical Trials Sites in China by Historical Volume
Top 10 Clinical Trial Investigators in China by Historical Volume
Top 10 Trials in China by Completed Enrollment Since 2019Marketed Products
Most Marketed Drugs in China Are Developed by Chinese Companies
Generics Have the Largest Share of Marketed Drugs in China
China's Position in the Global Generics Manufacturing Market
Leading Generics Manufacturers in China
Majority of Marketed Drugs Are for Bacterial Infections
The Majority of Biologics Are Used to Treat Infectious Disease
Most Companies Marketing Biologics in China Are Chinese
Examples of China-Made Biologics (Innovator, Vaccines, etc.)
Currently Approved COVID-19 Vaccines in China
China Leads in Number of COVID-19 Vaccinations
The Majority of Marketed Biosimilars Are Developed in China
Examples of Marketed Biosimilars in China
Many Marketed IO Drugs Are from International Companies
Examples of Immuno-oncology Drugs from Chinese Companies
Pipeline Products
Majority of Pipeline Drugs Are Developed by Chinese Companies
Majority of Pipeline Drugs Are in Phase II or Lower, and Most Are Innovator Biologics
Oncology Overwhelmingly Drives the Drug Pipeline in China
Most Innovator Biologics and Biosimilars Are Also in the Oncology Space
Examples of Late-Stage Pipeline Biologics in China
Examples of Late-Stage Pipeline Biosimilars in China
Regenerative Medicine Is a Rapidly Growing Sector in China
Most Pipeline Regenerative Medicines Are in Early Stages of Development by Chinese Research Institutes
The Highest Number of Regenerative Medicine Clinical Trials That Started in 2020 Were in China
However, Phase II and Phase III Trials Have Been Impacted By A Gene-Editing Scandal
Examples of Regenerative Medicines in China
Domestic Companies Are Developing the Vast Majority of Novel Pipeline Immuno-oncology Drugs in China
Majority of Pipeline Drugs Are in Phase II or Lower, and Most Are CAR-T Cell Therapies
Examples of Late-Stage Pipeline Immuno-oncology Drugs
Pipeline COVID-19 Vaccines and Treatments in China
Examples of Pipeline COVID-19 Vaccines and Treatments
Contract Manufacturing in China
Companies with Different Contacting Manufacturing Facilities in China
China Is a Global Leader in API Chemical Manufacturing
Outsourcing Deals for Biologic Manufacturing Are Increasing in China
WuXi Has the Most CDMO Facilities and Has Forged the Most Outsourcing Deals in China
West China Is Noticeably Lacking CDMO Facilities
Examples of Contract Manufacturing Deals - Biosimilars/Biologics
Examples of Contract Manufacturing Deals - Gene and Cell Therapy
Examples of Contract Manufacturing Deals - COVID-19
Regulatory and Market Access
Drug Approval Process in China
Regulatory Reforms in China
Regulation of Drugs in China
Market Access for Drugs in China
Market Drivers and Barriers
Market Drivers in China
Market Barriers in China
Companies
Appendix
Bibliography
Key Themes Impacting the Pharmaceutical Industry
Our Thematic Research Methodology
About the Authors
Contact Us
Disclaimer
Filed in: Information Technology
Publisher : GlobalData